<DOC>
	<DOCNO>NCT00000903</DOCNO>
	<brief_summary>To compare time virologic failure ( first 2 consecutive plasma HIV RNA level great equal 200 copies/ml Week 24 ) 4-drug regimen v 3-drug regimen . To determine safety , tolerance , virologic benefit either nelfinavir ( NFV ) efavirenz ( EFV ) indinavir/lamivudine/zidovudine ( IDV/3TC/ZDV ) v IDV/3TC/ZDV alone , treatment patient advance HIV disease receive limited prior antiretroviral therapy . Prior ACTG study show 3-drug combination regimen ( IDV/ZDV/3TC ) result improved clinical outcome therefore may prolong effect therapy . The enhanced effect see combination therapy likely relate great suppression RNA replication alteration resistance pattern . Due progressive success combination regimen , possible potent regimen enhance viral suppression provide durable treatment response . In light additive suppression HIV replication determine pharmacological , immunological , virological result , nelfinavir ( NFV ) addition IDV/ZDV/3TC evaluate . Based potency nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) suppress viral replication effectiveness 3-drug regimen contain NNRTIs , efavirenz ( EFV ) also evaluate addition IDV/ZDV/3TC .</brief_summary>
	<brief_title>Addition Efavirenz Nelfinavir Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen</brief_title>
	<detailed_description>Prior ACTG study show 3-drug combination regimen ( IDV/ZDV/3TC ) result improved clinical outcome therefore may prolong effect therapy . The enhanced effect see combination therapy likely relate great suppression RNA replication alteration resistance pattern . Due progressive success combination regimen , possible potent regimen enhance viral suppression provide durable treatment response . In light additive suppression HIV replication determine pharmacological , immunological , virological result , nelfinavir ( NFV ) addition IDV/ZDV/3TC evaluate . Based potency nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) suppress viral replication effectiveness 3-drug regimen contain NNRTIs , efavirenz ( EFV ) also evaluate addition IDV/ZDV/3TC . Patients HIV infection , CD4 cell count less equal 200 cells/mm3 plasma HIV RNA great equal 100,000 copies/ml , limited ( prior 3TC , NNRTI , protease inhibitor ) prior antiretroviral treatment randomize 1 3 arm . Patients stratify CD4 cell count ( less equal 50 cells/mm3 v great 50 cells/mm3 ) , HIV-1 RNA copy number ( less equal 40,000 copies/ml v great 40,000 copies/ml ) , prior antiretroviral therapy ( therapy v therapy ) , randomly assign 1 3 treatment arm : Arm 1 : 3TC plus ZDV plus IDV . Arm 2 : 3TC plus ZDV plus IDV plus EFV . Arm 3 : 3TC plus ZDV plus IDV plus NFV . Patients follow least 72 week [ AS PER AMENDMENT 2/16/99 : 96 week ] beyond enrollment last patient . Patients experience virologic relapse option continue randomize study medication , switch Step 2 treatment , switch another ACTG study , seek best available therapy remain week study . Step 2 treatment consist abacavir 2 NNRTIs plus efavirenz plus amprenavir another protease inhibitor . [ AS PER AMENDMENT 4/3/00 : Optimally , Step 2 treatment regimen contain 3 4 drug virus susceptible . If possible , drug virus partially susceptible acceptable , drug virus resistant include . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii pneumonia . Topical oral antifungal agent ( except oral ketoconazole itraconazole ) . All antibiotic clinically indicate ( unless otherwise exclude ) . Treatment , maintenance , chemoprophylaxis approve agent opportunistic infection clinically indicate ( unless otherwise exclude ) . Systemic corticosteroid 21 day less acute problem . Recombinant erythropoietin ( rEPO ) granulocyte colonystimulating factor ( GCSF , filgrastim ) . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive , megestrol acetate , testosterone . Alternative therapy vitamin . Patients report use therapy . [ AS PER AMENDMENT 2/16/99 : Rifabutin administer reduce dose . ] [ AS PER AMENDMENT 4/3/00 : Systemic cytotoxic chemotherapy . Study team notify . ] [ AS PER AMENDMENT 4/3/00 : Expanded access compassionate use drug allow part Step 2 treatment . ] Allowed caution : [ AS PER AMENDMENT 4/3/00 : Viagra ( sildenafil citrate ) reduce dose unless otherwise approve protocol chair . ] [ AS PER AMENDMENT 4/3/00 : Lovastatin simvastatin PIs recommend . Caution exercise use statin use concomitantly PIs . ] Concurrent Treatment : Allowed : Alternative therapy acupuncture visualization technique . Patients report use therapy . Patients must : Documented HIV1 infection . CD4 count less equal 200 cells/mm3 plasma HIV RNA great equal 100,000 copies/ml [ AS PER AMENDMENT 2/16/99 : 80,000 copies/ml ] within 60 day prior entry . Other lab value perform within 14 day prior entry . Prior Medication : Allowed : Zidovudine ( ZDV ) , didanosine ( ddI ) , stavudine ( d4T ) , zalcitabine ( ddC ) therapy alone combination time prior study entry . Exclusion Criteria Concurrent Medication : Excluded : All antiretroviral therapy study medication . [ AS PER AMENDMENT 4/3/00 : Compassionate use expand access drug allow part Step 2 treatment . ] Investigational drug without specific approval Study Chair . [ AS PER AMENDMENT 4/3/00 : Compassionate use expand access drug allow part Step 2 treatment . ] Systemic cytotoxic chemotherapy . [ AS PER AMENDMENT 4/3/00 : Systemic cytotoxic chemotherapy allow . Study team notify . ] Alprazolam , amiodarone , astemizole , bepridil , bupropion , cisapride , clorazepate , clozapine , diazepam , encainide , ergot alkaloids derivative ergot alkaloid , estazolam , flecainide , flurazepam , itraconazole , ketoconazole , meperidine , midazolam , piroxicam , propafenone , propoxyphene , quinidine , rifabutin , rifampin , terfenadine , triazolam , zolpidem . [ AS PER AMENDMENT 2/16/99 : Amiodarone , astemizole , cisapride , ergot alkaloid drug contain derivative ergot alkaloid , itraconazole , midazolam , triazolam , quinidine , rifampin , terfenadine . ] [ AS PER AMENDMENT 4/3/00 : Amiodarone , astemizole , bepridil , cisapride , ergot alkaloids derivative ergot alkaloid , Hypericum perforatum ( St. John 's wort ) , itraconazole , midazolam , quinidine , rifampin , terfenadine , triazolam . ] Vitamin E supplement . [ AS PER AMENDMENT 4/3/00 : Multivitamins contain vitamin E allow . ] Avoided : Herbal medication . Patients report use . Patients follow prior condition exclude : Acute therapy infection medical illness within 14 day prior study entry . [ AS PER AMENDMENT 2/16/99 : Acute therapy serious infection serious medical illness potentially lifethreatening require systemic therapy and/or hospitalization within 14 day study entry . ] Prior Medication : Excluded within 30 day prior entry : More 1 day experience lamivudine ( 3TC ) , nonnucleoside reverse transcriptase inhibitor , protease inhibitor . Erythropoietin , GCSF , GMCSF . Interferons , interleukins , HIV vaccine , experimental therapy . Excluded within 14 day prior entry : Alprazolam ( Xanax ) , amiodarone ( Cordarone ) , astemizole ( Hismanal ) , bepridil ( Vascor ) , bupropion ( Wellbutrin , Zyban ) , cisapride ( Propulsid ) , clorazepate ( Tranxene ) , clozapine ( Clozaril ) , diazepam ( Valium ) , encainide ( Enkaid ) , ergot alkaloid drug contain derivative ergot alkaloid , estazolam ( ProSom ) , flecainide ( Tambocor ) , flurazepam ( Dalmane ) , itraconazole ( Sporanox ) , ketoconazole ( Nizoral ) , meperidine ( Demerol ) , midazolam ( Versed ) , piroxicam ( Feldene ) , propafenone ( Rythmol ) , propoxyphene ( Darvon , Darvocet ) , quinidine , rifabutin ( Mycobutin ) , rifampin ( Rifadin , Rifamate , Rifater , Rimactane ) , terfenadine ( Seldane ) , triazolam ( Halcion ) , zolpidem ( Ambien ) . [ AS PER AMENDMENT 2/16/99 : Agents exclude within 14 day prior entry follow : amiodarone , astemizole , cisapride , ergot alkaloid drug contain derivative ergot alkaloid , itraconazole , midazolam , quinidine , rifampin , terfenadine , triazolam . Note : Rifabutin administer reduce dose 150 mg/day . ]</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>efavirenz</keyword>
</DOC>